
Workshop 4 – Antimicrobial Resistance & Vaccines

Dennis M. Dixon, PhD

Chief, Bacteriology and Mycology Branch
Division of Microbiology and Infectious Diseases
NIAID, NIH, HHS



March 16, 2016
Johannesburg, South Africa



National Institute of
Allergy and
Infectious Diseases

Agenda for Workshop 4


11:15-12:30 (75 min)

Chair	Dennis Dixon (NIAID)
Speakers	<ol style="list-style-type: none">1. Martin Friede (WHO) and Bruce Gellin (NVPO, U.S. DHHS) : The role of vaccines in AMR strategies2. Olaf Schneewind (U. of Chicago, USA): Staphylococcal Vaccines3. Magnus Unemo (Örebro U. Hospital, Sweden): Gonococcal Vaccines4. Jordi Rello (Vall d'Hebron U. Hospital, Spain): Vaccines for Gram-Negative Healthcare Pathogens No ESKAPE

National Action Plan for Combating Antibiotic-Resistance Bacteria (CARB)

■ Plan goals for CARB:

- Stewardship
- Surveillance
- Diagnostics
- Research *Vaccine research*
- International Collaboration



CDC AR Threat Category

- Urgent
 - Drug-resistant *Neisseria gonorrhoeae*

- Serious
 - MDR *Pseudomonas aeruginosa*
 - MRSA

- Concerning
 - VRSA

Vaccines to Reduce Antibacterial Resistance: 2 Examples

- Strategy 1: Prevent Bacterial Infections
 - Support for *Staphylococcus aureus* vaccines
 - Investigator-initiated R01s and SBIRs
 - Preclinical services to advance product development
 - 2010 and 2013 workshops to advance the field
- Strategy 2: prevent viral respiratory infections
 - Basic, translational and clinical support for influenza and RSV vaccines